乳がんリキッドバイオプシーの世界市場：成長、将来展望、競合分析 (2024年～2032年)

乳がんリキッドバイオプシー市場は、2024年から2032年の予測期間中にCAGR 22.7%で成長すると予測されています。乳がんリキッドバイオプシー市場は、非侵襲的なリキッドバイオプシーを活用し、血液サンプルを通じて乳がんを検出・モニタリングする急速に発展している分野です。この方法は、従来の組織生検よりも大きな進歩をもたらし、腫瘍の動態に関するリアルタイムの洞察を提供し、個別化された治療戦略を可能にします。がんの発見と管理に革命をもたらす可能性を秘めたこの技術は、腫瘍学研究と臨床応用の最前線に位置づけられています。

促進要因

ゲノム技術の進歩

ゲノムシークエンシングと解析の技術的進歩は、乳がんリキッドバイオプシー市場を牽引する極めて重要な要素です。次世代シーケンシング (NGS) およびポリメラーゼ連鎖反応 (PCR) 技術が高度化するにつれて、乳がんの遺伝的基盤に関する深い洞察が得られるようになり、血流中の微量の腫瘍DNAの検出が可能になった。これらの進歩は、リキッドバイオプシーの感度と特異性を向上させただけでなく、早期発見、予後予測、治療効果と耐性のモニタリングなど、その応用の可能性を広げています。ゲノム技術の継続的な向上は、臨床現場におけるリキッドバイオプシーの採用拡大におけるその役割を裏付けています。

非侵襲的手順への需要の高まり

非侵襲的診断手技に対する患者や医療提供者の嗜好の高まりも、乳がんリキッドバイオプシー市場の重要な促進要因です。従来の組織生検は効果的ではあるが侵襲的であり、しばしば不快感や潜在的合併症を引き起こします。対照的に、リキッドバイオプシーは、簡単な採血で実施できる低侵襲の代替法を提供し、患者のストレスとリスクを軽減します。このような患者に優しいアプローチは、腫瘍の進行や治療に対する反応をモニタリングするために必要な繰り返し検査に特に有利であり、リキッドバイオプシーは継続的な疾患管理のための魅力的な選択肢となっています。

乳がんの有病率の上昇

乳がんの世界の有病率の上昇は、効果的な診断・モニタリングツールに対する需要を著しく煽り、リキッドバイオプシー市場を押し上げています。乳がんは世界で最も一般的ながんの1つであり、早期発見と患者の転帰改善につながる診断技術の進歩が急務です。リキッドバイオプシーは、血液サンプルからがんを初期段階で検出できるツールを提供することでこのニーズに応え、タイムリーな介入と個別化治療計画を促進します。世界の乳がん罹患率の増加は、リキッドバイオプシー・ソリューションの開発と採用の有力な促進要因です。

阻害要因

規制と償還の課題

乳がんリキッドバイオプシー市場の潜在力と成長にもかかわらず、規制と償還の課題という大きな抑制要因に直面しています。リキッドバイオプシー検査は新規性が高く複雑であるため、FDAのような機関から規制当局の承認を得るにはハードルが高いです。さらに、リキッドバイオプシーの使用と解釈に関する標準化されたガイドラインがないことも、規制上の課題に拍車をかけています。保険償還の面では、リキッドバイオプシーの保険適用が不十分で保険償還方針が不明確であるため、医療プロバイダーがこの技術を採用するのを躊躇する可能性があります。こうした規制と償還の問題は、市場の成長と普及を遅らせる実質的な障害となっています。

バイオマーカーによる市場セグメンテーション

乳がんリキッドバイオプシー市場は、循環腫瘍細胞 (CTC)、無細胞DNA (cfDNA)、エクソソーム、その他のバイオマーカーなどのバイオマーカー別にセグメント化されています。中でもcfDNAは、微小残存病変や治療抵抗性の検出・モニタリングにおける臨床的有用性が高いため、収益面でリードしています。cfDNAは、腫瘍の遺伝学に関する迅速かつ非侵襲的な洞察を提供できるため、臨床現場で好まれています。さらに、cfDNAは、シーケンス技術の継続的な進歩と臨床採用の増加により、予測期間中に最も高い年間平均成長率 (CAGR) を示すと予測されています。一方、CTCも、特に転移プロセスを理解する上で重要な役割を担っていますが、その分離と分析に関連する技術的課題のため、市場のごく一部を占めているにすぎません。エクソソームは、腫瘍の挙動や治療に対する反応に関する洞察を提供する可能性のある包括的な分子情報を提供するため、人気を集めています。タンパク質や代謝物を含むその他のバイオマーカーは、研究が進んでおり、既存のバイオマーカーを補完して、より詳細な疾患プロファイリングや治療効果の評価を可能にする可能性があるため、有望視されています。

製品・サービス別市場セグメンテーション

乳がんリキッドバイオプシー市場では、製品・サービス別にキット・試薬とサービスがセグメンテーションされています。キット・試薬はリキッドバイオプシー検査で使用される基礎的な構成要素であるため、収益面で優位を占めています。この分野は、患者の治療経過にわたって複数段階の検査を行うリキッドバイオプシー検査に関連して、頻繁に消費され、定期的に購入されることから利益を得ています。さらに、精度と効率の向上を目指した試薬とキットの継続的な技術革新が、高い収益を支えています。一方、CAGRが最も高いと予想されるのはサービスです。この成長は、検査実施、データ分析、実用的な洞察を含む包括的なサービス提供に対する嗜好の高まりに後押しされています。専門的な診断サービスの増加や、高度なリキッドバイオプシー技術に対応するための検査施設の能力拡張は、このセグメントの成長に大きく寄与しています。

地理的動向

乳がんリキッドバイオプシー市場はダイナミックな地理的動向を示しており、北米は高度な医療インフラ、がん検診に対する高い意識、主要市場プレイヤーの存在により、現在収益面でリードしています。しかし、アジア太平洋地域は、医療費の増加、患者の意識の向上、医療施設の改善などを背景に、2024年から2032年にかけて最も高い年間平均成長率 (CAGR) を示すと予想されています。中国やインドのような国々で乳がんの有病率が高まっていることと、医療技術への投資が増加していることが、この地域の急成長を後押ししています。欧州もまた、がん診断薬に関する強力な規制の枠組みや多額の医療費に支えられ、市場で大きなシェアを維持しています。

競合動向

乳がんリキッドバイオプシー市場は、Datar Cancer Genetics、Epic Sciences、F. Hoffmann-La Roche、Genes2me、Illumina、Menarini Silicon Biosystems、Myriad Genetics、OncoDNA、QIAGEN、Sysmex、System Biosciences、Thermo Fisher Scientific、Twist Bioscienceといった企業の参入が目立っています。これらの企業は様々な戦略を駆使して市場での地位を固め、収益源を拡大してきました。2022年には、これらの企業は市場での優位性と革新的な能力を反映し、多額の収益を計上しました。2024年から2032年までの予測期間におけるこれらの企業の戦略は、技術革新、M&A、地理的拡大に重点を置くと予想されます。例えば、これらの企業の多くは、リキッドバイオプシーの精度と信頼性を高めるために、高度なゲノム技術を統合して製品ラインを強化しています。また、特にアジア太平洋やラテンアメリカの未開拓市場など、世界な事業拡大を目指す企業にとって、提携や協力関係も極めて重要です。さらに、研究開発への投資はこれらの企業にとって主要な戦略であり、新規バイオマーカーの発見や既存のリキッドバイオプシー技術の感度向上をリードすることを目指しています。このような戦略的努力は、世界の市場全体の拡大動向と一致し、今後数年間におけるこれら企業の継続的成長と競合優位性を促進すると予想されます。

目次

第1章 序文

• 分析内容
  • 分析の目的
  • 対象者
  • 主な提供内容
• 市場セグメンテーション
• 分析手法
  • フェーズⅠ：二次調査
  • フェーズⅡ：一次調査
  • フェーズⅢ：有識者レビュー
  • 前提条件
  • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 乳がんリキッドバイオプシー市場：競合分析

• 主要ベンダーの市場ポジショニング
• ベンダーが採用した戦略
• 主要な産業戦略

第4章 乳がんリキッドバイオプシー市場：マクロ分析と市場力学

• イントロダクション
• 世界の乳がんリキッドバイオプシー市場 (金額ベース、2022～2032年)
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析
• ポーターのファイブフォースモデル
  • サプライヤーパワー
  • バイヤーパワー
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係
• PESTEL分析
  • 政治的情勢
  • 経済的情勢
  • 技術的情勢
  • 法的情勢
  • 社会的情勢

第5章 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 循環腫瘍細胞 (CTC)
  • 遊離DNA (cfDNA)
  • エクソソーム
  • その他のバイオマーカー

第6章 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • キット・試薬
  • サービス

第7章 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 血
  • 尿
  • その他の種類の試料

第8章 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 病院
  • がん研究センター
  • 診断センター
  • 学術研究機関

第9章 北米の乳がんリキッドバイオプシー市場 (2022～2032年)

• 市場概要
• 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：地域別 (2022～2032年)
  • 北米
    • 米国
    • カナダ
    • その他北米地域

第10章 英国・EU諸国の乳がんリキッドバイオプシー市場 (2022～2032年)

• 市場概要
• 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：地域別 (2022～2032年)
  • 英国・EU諸国
    • 英国
    • ドイツ
    • スペイン
    • イタリア
    • フランス
    • その他欧州地域

第11章 アジア太平洋の乳がんリキッドバイオプシー市場 (2022～2032年)

• 市場概要
• 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：地域別 (2022～2032年)
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域

第12章 ラテンアメリカの乳がんリキッドバイオプシー市場 (2022～2032年)

• 市場概要
• 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：地域別 (2022～2032年)
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域

第13章 中東・アフリカの乳がんリキッドバイオプシー市場 (2022～2032年)

• 市場概要
• 乳がんリキッドバイオプシー市場：バイオマーカー別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：製品・サービス別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：試料の種類別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：最終用途別 (2022～2032年)
• 乳がんリキッドバイオプシー市場：地域別 (2022～2032年)
  • 中東・アフリカ
    • GCC
    • アフリカ
    • その他中東・アフリカ地域

第14章 企業プロファイル

• Datar Cancer Genetics
• Epic Sciences
• F. Hoffmann-La Roche
• Genes2me
• Illumina
• Menarini Silicon Biosystems
• Myriad Genetics
• OncoDNA
• QIAGEN
• Sysmex
• System Biosciences
• Thermo Fisher Scientific
• Twist Bioscience
• その他の主要企業

List of Tables

• TABLE 1 Global Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 2 Global Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 3 Global Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 4 Global Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 5 North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 6 North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 7 North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 8 North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 9 U.S. Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 10 U.S. Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 11 U.S. Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 12 U.S. Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 13 Canada Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 14 Canada Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 15 Canada Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 16 Canada Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 17 Rest of North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 18 Rest of North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 19 Rest of North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 20 Rest of North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 21 UK and European Union Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 22 UK and European Union Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 23 UK and European Union Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 24 UK and European Union Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 25 UK Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 26 UK Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 27 UK Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 28 UK Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 29 Germany Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 30 Germany Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 31 Germany Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 32 Germany Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 33 Spain Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 34 Spain Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 35 Spain Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 36 Spain Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 37 Italy Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 38 Italy Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 39 Italy Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 40 Italy Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 41 France Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 42 France Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 43 France Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 44 France Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 45 Rest of Europe Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 46 Rest of Europe Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 47 Rest of Europe Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 48 Rest of Europe Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 49 Asia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 50 Asia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 51 Asia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 52 Asia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 53 China Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 54 China Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 55 China Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 56 China Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 57 Japan Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 58 Japan Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 59 Japan Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 60 Japan Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 61 India Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 62 India Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 63 India Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 64 India Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 65 Australia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 66 Australia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 67 Australia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 68 Australia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 69 South Korea Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 70 South Korea Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 71 South Korea Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 72 South Korea Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 73 Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 74 Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 75 Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 76 Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 77 Brazil Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 78 Brazil Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 79 Brazil Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 80 Brazil Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 81 Mexico Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 82 Mexico Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 83 Mexico Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 84 Mexico Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 85 Rest of Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 86 Rest of Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 87 Rest of Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 88 Rest of Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 89 Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 90 Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 91 Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 92 Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 93 GCC Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 94 GCC Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 95 GCC Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 96 GCC Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 97 Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 98 Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 99 Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 100 Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
• TABLE 101 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
• TABLE 102 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
• TABLE 103 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
• TABLE 104 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)

List of Figures

• FIG. 1 Global Breast Cancer Liquid Biopsy Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Breast Cancer Liquid Biopsy Market: Quality Assurance
• FIG. 5 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023
• FIG. 6 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023
• FIG. 7 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023
• FIG. 8 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023
• FIG. 9 Global Breast Cancer Liquid Biopsy Market, By Geography, 2023
• FIG. 10 Market Geographical Opportunity Matrix - Global Breast Cancer Liquid Biopsy Market, 2023
• FIG. 11Market Positioning of Key Breast Cancer Liquid Biopsy Market Players, 2023
• FIG. 12Global Breast Cancer Liquid Biopsy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
• FIG. 13 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 Vs 2032, %
• FIG. 14 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 Vs 2032, %
• FIG. 15 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 Vs 2032, %
• FIG. 16 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 Vs 2032, %
• FIG. 17 U.S. Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 18 Canada Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 19 Rest of North America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 20 UK Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 21 Germany Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 22 Spain Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 23 Italy Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 24 France Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 25 Rest of Europe Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 26 China Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 27 Japan Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 28 India Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 29 Australia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 30 South Korea Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 31 Rest of Asia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 32 Brazil Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 33 Mexico Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 34 Rest of Latin America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 35 GCC Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 36 Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
• FIG. 37 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032

The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies. The technology's potential to revolutionize cancer detection and management has positioned it at the forefront of oncology research and clinical application.

Drivers

Advancements in Genomic Technologies

Technological advancements in genomic sequencing and analysis have been pivotal in driving the breast cancer liquid biopsy market. As next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have become more sophisticated, they offer deeper insights into the genetic basis of breast cancer, enabling the detection of minute quantities of tumor DNA in the bloodstream. These advancements have not only enhanced the sensitivity and specificity of liquid biopsies but have also broadened their potential applications, including early detection, prognosis, and monitoring of therapeutic efficacy and resistance. The continuous improvements in genomic technologies underscore their role in the growing adoption of liquid biopsies in clinical settings.

Growing Demand for Non-Invasive Procedures

The increasing preference for non-invasive diagnostic procedures among both patients and healthcare providers is another significant driver for the breast cancer liquid biopsy market. Traditional tissue biopsies, while effective, are invasive and often lead to discomfort and potential complications. In contrast, liquid biopsies offer a minimally invasive alternative that can be performed with a simple blood draw, reducing patient stress and risk. This patient-friendly approach is particularly advantageous for repeated testing required in monitoring tumor progression and response to treatment, making liquid biopsies an attractive option for continuous disease management.

Rising Prevalence of Breast Cancer

The rising global prevalence of breast cancer significantly fuels the demand for effective diagnostic and monitoring tools, boosting the liquid biopsy market. With breast cancer being one of the most common cancers worldwide, there is an urgent need for advancements in diagnostic techniques that can lead to earlier detection and improved patient outcomes. Liquid biopsies meet this need by providing a tool that can detect cancer at its earliest stages from a blood sample, facilitating timely intervention and personalized treatment plans. The increasing incidence of breast cancer globally is a compelling driver for the development and adoption of liquid biopsy solutions.

Restraint

Regulatory and Reimbursement Challenges

Despite the potential and growth of the breast cancer liquid biopsy market, it faces significant restraints with regulatory and reimbursement challenges. The novelty and complexity of liquid biopsy tests pose hurdles in gaining regulatory approvals from bodies like the FDA, as these agencies require extensive validation of the tests' clinical utility and accuracy before they can be broadly implemented. Furthermore, the lack of standardized guidelines for the use and interpretation of liquid biopsies adds to the regulatory challenges. On the reimbursement front, insufficient coverage and unclear reimbursement policies for liquid biopsies can deter healthcare providers from adopting this technology, as the financial costs of these advanced tests are often higher than traditional methods. These regulatory and reimbursement issues are substantial obstacles that slow the market's growth and widespread adoption.

Market Segmentation by Biomarkers

The breast cancer liquid biopsy market is segmented by biomarkers, including Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Exosomes, and Other Biomarkers. Among these, cfDNA leads in revenue generation due to its high clinical utility in detecting and monitoring minimal residual disease and treatment resistance. Its ability to provide rapid, non-invasive insights into tumor genetics makes cfDNA a preferred choice in clinical settings. Furthermore, cfDNA is projected to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period, driven by continuous advancements in sequencing technologies and increasing clinical adoption. On the other hand, CTCs also play a crucial role, particularly in understanding metastatic processes, though they capture a smaller portion of the market due to the technical challenges associated with their isolation and analysis. Exosomes are gaining traction as they provide comprehensive molecular information that potentially offers insights into tumor behavior and response to therapy. The segment of Other Biomarkers, which includes proteins and metabolites, shows promise due to ongoing research and potential to complement existing biomarkers for a more detailed disease profiling and treatment efficacy evaluation.

Market Segmentation by Products & Services

In the breast cancer liquid biopsy market, segmentation by Products & Services includes Kits & Reagents and Services. Kits & Reagents dominate in terms of revenue, as they are the foundational components used in liquid biopsy tests. This segment benefits from the frequent consumption and recurring purchases associated with liquid biopsy procedures, which involve multiple stages of testing over a patient's treatment course. Additionally, the ongoing innovation in reagents and kits, aimed at enhancing accuracy and efficiency, supports their high revenue generation. Meanwhile, Services are expected to witness the highest CAGR. This growth is fueled by the increasing preference for comprehensive service offerings that include test execution, data analysis, and actionable insights, which are highly valued in clinical settings for making informed treatment decisions. The rise in specialized diagnostic services and the expansion of laboratory capabilities to accommodate advanced liquid biopsy technologies contribute significantly to the growth of this segment.

Geographic Trends

The breast cancer liquid biopsy market demonstrates dynamic geographic trends, with North America currently leading in terms of revenue due to its advanced healthcare infrastructure, high awareness about cancer screenings, and the presence of key market players. However, Asia-Pacific is expected to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2032, driven by rising healthcare expenditures, increasing patient awareness, and improving healthcare facilities. The growing prevalence of breast cancer in countries like China and India, coupled with increasing investments in healthcare technologies, fuels the rapid growth in this region. Europe also maintains a significant share in the market, supported by its strong regulatory frameworks for cancer diagnostics and substantial healthcare spending.

Competitive Trends

In terms of competitive trends, the market sees robust participation from companies like Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience. These entities have leveraged various strategies to solidify their market positions and expand their revenue streams. In 2022, these companies reported substantial revenues, reflecting their dominance and innovative capabilities within the market. Their strategies for the forecast period of 2024 to 2032 are expected to focus on technological innovations, mergers and acquisitions, and geographic expansion. For instance, many of these firms are enhancing their product lines with integrations of advanced genomic technologies to increase the accuracy and reliability of liquid biopsies. Partnerships and collaborations are also crucial as companies aim to expand their global footprints, particularly in untapped markets within Asia-Pacific and Latin America. Moreover, investment in research and development is a key strategy for these companies, aiming to lead in the discovery of novel biomarkers and improve the sensitivity of existing liquid biopsy techniques. These strategic efforts are anticipated to drive the continued growth and competitive edge of these companies in the upcoming years, aligning with the overall expansion trends seen across the global market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Breast Cancer Liquid Biopsy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Breast Cancer Liquid Biopsy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

• Market Segmentation
• Biomarkers

• Circulating tumor cells (CTCs)

• Cell-free DNA (cfDNA)

• Exosomes

• Other biomarkers
• Products & Services

• Kits & reagents

• Services
• Sample Type

• Blood

• Urine

• Other sample types
• End Use

• Hospitals

• Cancer research centers

• Diagnostic centers

• Academic and research institutes
• Region Segment (2022-2032; US$ Million)
• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Liquid Biopsy market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Breast Cancer Liquid Biopsy market?
• Which is the largest regional market for Breast Cancer Liquid Biopsy market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Breast Cancer Liquid Biopsy market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Liquid Biopsy market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
• 2.2. Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 (US$ Million)
• 2.3. Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 (US$ Million)
• 2.4. Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 (US$ Million)
• 2.5. Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 (US$ Million)
• 2.6. Global Breast Cancer Liquid Biopsy Market, By Geography, 2023 (US$ Million)
• 2.7. Attractive Investment Proposition by Geography, 2023

3. Breast Cancer Liquid Biopsy Market: Competitive Analysis

• 3.1. Market Positioning of Key Breast Cancer Liquid Biopsy Market Vendors
• 3.2. Strategies Adopted by Breast Cancer Liquid Biopsy Market Vendors
• 3.3. Key Industry Strategies

4. Breast Cancer Liquid Biopsy Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Breast Cancer Liquid Biopsy Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Circulating tumor cells (CTCs)
  • 5.3.2. Cell-free DNA (cfDNA)
  • 5.3.3. Exosomes
  • 5.3.4. Other biomarkers

6. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Kits & reagents
  • 6.3.2. Services

7. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Blood
  • 7.3.2. Urine
  • 7.3.3. Other sample types

8. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Growth & Revenue Analysis: 2023 Versus 2032
• 8.3. Market Segmentation
  • 8.3.1. Hospitals
  • 8.3.2. Cancer research centers
  • 8.3.3. Diagnostic centers
  • 8.3.4. Academic and research institutes

9. North America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
• 9.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
• 9.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
• 9.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
• 9.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
  • 9.6.1.North America
    • 9.6.1.1. U.S.
      • 9.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 9.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 9.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 9.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 9.6.1.2. Canada
      • 9.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 9.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 9.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 9.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 9.6.1.3. Rest of North America
      • 9.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 9.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 9.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 9.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

10. UK and European Union Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
• 10.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
• 10.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
• 10.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
• 10.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
  • 10.6.1.UK and European Union
    • 10.6.1.1. UK
      • 10.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 10.6.1.2. Germany
      • 10.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 10.6.1.3. Spain
      • 10.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 10.6.1.4. Italy
      • 10.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 10.6.1.5. France
      • 10.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 10.6.1.6. Rest of Europe
      • 10.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 10.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 10.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 10.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

11. Asia Pacific Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
• 11.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
• 11.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
• 11.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
• 11.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
  • 11.6.1.Asia Pacific
    • 11.6.1.1. China
      • 11.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 11.6.1.2. Japan
      • 11.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 11.6.1.3. India
      • 11.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 11.6.1.4. Australia
      • 11.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 11.6.1.5. South Korea
      • 11.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 11.6.1.6. Rest of Asia Pacific
      • 11.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 11.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 11.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 11.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

12. Latin America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
• 12.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
• 12.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
• 12.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
• 12.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
  • 12.6.1.Latin America
    • 12.6.1.1. Brazil
      • 12.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 12.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 12.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 12.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 12.6.1.2. Mexico
      • 12.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 12.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 12.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 12.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 12.6.1.3. Rest of Latin America
      • 12.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 12.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 12.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 12.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

13. Middle East and Africa Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

• 13.1. Market Overview
• 13.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
• 13.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
• 13.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
• 13.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
• 13.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
  • 13.6.1.Middle East and Africa
    • 13.6.1.1. GCC
      • 13.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 13.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 13.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 13.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 13.6.1.2. Africa
      • 13.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 13.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 13.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 13.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
    • 13.6.1.3. Rest of Middle East and Africa
      • 13.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
      • 13.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
      • 13.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
      • 13.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

14. Company Profile

• 14.1. Datar Cancer Genetics
  • 14.1.1. Company Overview
  • 14.1.2. Financial Performance
  • 14.1.3. Product Portfolio
  • 14.1.4. Strategic Initiatives
• 14.2. Epic Sciences
  • 14.2.1. Company Overview
  • 14.2.2. Financial Performance
  • 14.2.3. Product Portfolio
  • 14.2.4. Strategic Initiatives
• 14.3. F. Hoffmann-La Roche
  • 14.3.1. Company Overview
  • 14.3.2. Financial Performance
  • 14.3.3. Product Portfolio
  • 14.3.4. Strategic Initiatives
• 14.4. Genes2me
  • 14.4.1. Company Overview
  • 14.4.2. Financial Performance
  • 14.4.3. Product Portfolio
  • 14.4.4. Strategic Initiatives
• 14.5. Illumina
  • 14.5.1. Company Overview
  • 14.5.2. Financial Performance
  • 14.5.3. Product Portfolio
  • 14.5.4. Strategic Initiatives
• 14.6. Menarini Silicon Biosystems
  • 14.6.1. Company Overview
  • 14.6.2. Financial Performance
  • 14.6.3. Product Portfolio
  • 14.6.4. Strategic Initiatives
• 14.7. Myriad Genetics
  • 14.7.1. Company Overview
  • 14.7.2. Financial Performance
  • 14.7.3. Product Portfolio
  • 14.7.4. Strategic Initiatives
• 14.8. OncoDNA
  • 14.8.1. Company Overview
  • 14.8.2. Financial Performance
  • 14.8.3. Product Portfolio
  • 14.8.4. Strategic Initiatives
• 14.9. QIAGEN
  • 14.9.1. Company Overview
  • 14.9.2. Financial Performance
  • 14.9.3. Product Portfolio
  • 14.9.4. Strategic Initiatives
• 14.10. Sysmex
  • 14.10.1. Company Overview
  • 14.10.2. Financial Performance
  • 14.10.3. Product Portfolio
  • 14.10.4. Strategic Initiatives
• 14.11. System Biosciences
  • 14.11.1. Company Overview
  • 14.11.2. Financial Performance
  • 14.11.3. Product Portfolio
  • 14.11.4. Strategic Initiatives
• 14.12. Thermo Fisher Scientific
  • 14.12.1. Company Overview
  • 14.12.2. Financial Performance
  • 14.12.3. Product Portfolio
  • 14.12.4. Strategic Initiatives
• 14.13. Twist Bioscience
  • 14.13.1. Company Overview
  • 14.13.2. Financial Performance
  • 14.13.3. Product Portfolio
  • 14.13.4. Strategic Initiatives
• 14.14. Other Notable Players
  • 14.14.1. Company Overview
  • 14.14.2. Financial Performance
  • 14.14.3. Product Portfolio
  • 14.14.4. Strategic Initiatives